Clinical trial
Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy
NCT00396721 · Josep m Cruzado, Other · Completed
Key facts
| NCT number | NCT00396721 |
|---|---|
| Title | Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy |
| Official title | Pilot Trial of Treatment of Poor-Prognosis IgA Nephropathy With Low Exposure to Sirolimus. |
| Acronym | SIREPNA |
| Lead sponsor | Josep m Cruzado, Other |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glomerulonephritis, IGA, Nephropathy, IGA Nephropathy |
| Intervention type | Drug |
| Interventions | ACE inhibitor + statin, Sirolimus (study drug)+ACE inhibitor + statin |
| Enrollment | 23 |
| Start date | Jan 1, 2006 |
| Primary completion | Oct 1, 2009 |
| Completion | Feb 1, 2010 |
| First posted | Nov 7, 2006 |
| Last update posted | Sep 16, 2011 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: